The natural history of multiple myeloma has been revolutionized in recent decades thanks to knowledge in biology and immunology about the mechanisms of progression and resistance, as well as targeted therapeutic strategies, with a significant effect on the prognosis of patients. . Several families of drugs have been incorporated that change the treatment paradigm, including proteasome inhibitors (bortezomib and carfilzomib), immunomodulators (thalidomide, lenalidomide and pomalidomide) and anti-CD38 monoclonal antibodies. Especially after the great advances in immunotherapy, new molecules are emerging on the horizon, such as bispecific antibodies and CAR T lymphocytes, among others.

The complexity of patient diagnosis and treatment has increased, which is why multidisciplinary groups have been created. Consequently, it is increasingly necessary for specialists to have more specific knowledge in molecular biology, genetics, genomics, clinical and translational research, and new therapies with their complications.

The essential objectives of the chair are the promotion of a whole set of teaching, training, information and documentation activities in the field of monoclonal gammopathies.